A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The Epidermal Growth Factor Receptor (EGFR) is a validated target for the treatment of
cancer, and agents targeting EGFR such as erlotinib (Tarceva®) are approved by the FDA for
treatment of various solid tumors. AV-412 is a novel inhibitor of the EGFR-tyrosine kinase,
with added activity against Her2 and other oncogenic kinases. Based on evidence of
preclinical activity in various solid tumors, AV-412 is being developed as a possible novel
treatment for cancer in humans.
PURPOSE: The purpose of this study is to test the safety and tolerability of AV-412, and
determine the maximum tolerated dose of AV-412 when administered orally three times weekly.